Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Breast 1

Conditions

Advanced Non-Small Cell Lung Cancer 1

Interventions

pembrolizumab 27Pemetrexed 15Cisplatin 15Carboplatin 15Paclitaxel 14Nivolumab 10Cyclophosphamide 10Docetaxel 9atezolizumab 7Injections 7Melphalan 6tislelizumab 5olaparib 5Leucovorin 5Irinotecan 5Gemcitabine 5Filgrastim 5Bevacizumab 5durvalumab 4aldesleukin 4Oxaliplatin 4Granulocyte Colony-Stimulating Factor 4Fluorouracil 4Etoposide 4tocilizumab 3spartalizumab 3liposomal doxorubicin 3ixabepilone 3fludarabine 3epacadostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × WW Domain-Containing Oxidoreductase × Other solid neoplasm × Clear all
NCT00064636 2005-06-24

Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Millennium Pharmaceuticals, Inc.

Phase 1 Terminated
46 enrolled
Other solid neoplasmThoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡